Novavax Inc at JPMorgan Healthcare Conference Transcript
All right. Good morning. I'm Eric Joseph, senior biotech analyst here at JPMorgan. Our next presenting company is Novavax, and to tell us a little bit about the company is CFO, John Trizzino. The breakout session with the Q&A following the presentation is in the Olympic Room. With that, John?
Great. Thank you. Good morning, everybody. John Trizzino, CFO, Chief Business Officer from Novavax. And for those of you who are not familiar with Novavax, we are a late-stage biotechnology company focused on the development and commercialization of innovative vaccines that prevent serious and infectious diseases. And so the plan for today is to take you through some important elements of value-creating events that are going to be coming up in 2020 for the company, most significantly is our NanoFlu Phase III clinical trial, with data expected at the end of the first quarter. Oh, we're not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
